Precision medicine is redefining the future of healthcare by using genetic and biomarker testing to deliver treatments tailored to each patient’s unique biology. This personalized approach has the power to improve outcomes, reduce ineffective treatments, and save lives. Yet as Avalon CEO Bill Kerr, MD, explains, adoption remains uneven. Many patients, particularly those with cancers such as non-small cell lung cancer, miss out on critical testing or experience delays that limit their access to the most effective therapies. Bridging this gap is essential for realizing the full promise of precision medicine.
Health plans play a central role in making precision medicine more accessible. To keep pace with rapid scientific advancements, coverage policies must be regularly updated, coding systems streamlined, and provider collaboration strengthened. By aligning policies with the latest evidence and ensuring patients receive the right tests and therapies, health plans can drive better health outcomes while improving efficiency and reducing costs. Learn more about the benefits and challenges of precision medicine in Dr. Kerr’s article in Managed Healthcare Executive.
